



## Granules India Limited

Regd. Off. :

2nd Floor, 3rd Block, My Home Hub, Madhapur, Hyderabad - 500 081. INDIA

Ph : +91-40-30660000, 66760000 Fax : +91-40-23115145

E-mail : mail@granulesindia.com URL : www.granulesindia.com

CIN : L24110TG1991PLC012471

**Dated May 30, 2016**

To,  
National Stock Exchange of India Limited  
Bombay Stock Exchange Limited  
Symbol: NSE: GRANULES; BSE: 532482

**Sub: Receipt of Establishment Inspection Report (EIR) from US FDA -Press Release-Reg.**

**Ref: Our letter dated 21<sup>st</sup> December 2015 under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Dear Sir,


With reference to the captioned subject, please find herewith a copy of Press Release issued by the Company.

This is for your information and dissemination to the members of the exchange.

Thanking You.

Yours faithfully,

**For GRANULES INDIA LIMITED**

*T. Chaitanya*  
  
**CHAITANYA TUMMALA**  
**(COMPANY SECRETARY &**  
**COMPLIANCE OFFICER)**



*Press Release*

**Granules India's Jeedimetla plant received Establishment Inspection Report (EIR) from the US FDA**

Hyderabad, May 30, 2016: Granules India Ltd., a growing pharmaceutical manufacturing company, announced today that it has received the Establishment Inspection Report (EIR) from the US FDA for the inspection conducted at its Jeedimetla facility in December 2015.

The Company stated that, the US FDA acknowledged receipt of its responses sent on 7th January and 28th March 2016 on the observations issued by the US FDA for the Jeedimetla facility. The US FDA closed the matter and issued Establishment inspection report (EIR) for the Jeedimetla facility situated in the state of Telangana, India.

**About Granules India Ltd.**

(BSE: 532482, NSE: GRANULES)

Granules is a fast growing pharmaceutical manufacturing company with world class facilities and is committed to manufacturing excellence, quality and customer service. The Company produces Finished Dosages (FDs), Pharmaceutical Formulation Intermediates (PFIs) and Active Pharmaceutical Ingredients (APIs) for quality conscious customers in the regulated and semi-regulated markets. Granules support customers with unique value, extensive product range, proactive solutions and a global network of associates. The Company's global presence extends to over 300 customers in 60 countries through offices in India, U.S., U.K., China and Colombia. Granules offer all three components of the pharmaceutical value chain which gives the customers flexibility and choice.

The Company has its own ANDAs and dossiers which enable customers to quickly enter a market instead of filing their own applications. Granules has a highly skilled regulatory affairs department that can offer customers support and can help them navigate through regulatory issues.

**Caution Statement:**

Certain statements made above may be "forward looking statements" within the meaning of applicable laws and regulations.

**Contacts:**

Sumanta Bajpayee  
Granules India Ltd.  
040-30663572  
sumanta.bajpayee@granulesindia.com

Govindan JM  
Genesis Burson-Marsteller  
+91 9703700884  
Govindan.JM@bm.com